FDA Announces Regulatory Actions to Accelerate Psychedelic Development for Serious Mental Health Conditions
- Food and Drug Administration announced a series of regulatory actions on April 24, 2026, to accelerate the development of psychedelic-based therapies for serious mental health conditions, following an...
- The FDA’s actions build on the executive order directing the Department of Health and Human Services to expand access to treatments for patients with serious mental illness, including...
- Under President Trump’s leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis...
The U.S. Food and Drug Administration announced a series of regulatory actions on April 24, 2026, to accelerate the development of psychedelic-based therapies for serious mental health conditions, following an executive order signed by President Trump on April 18, 2026.
The FDA’s actions build on the executive order directing the Department of Health and Human Services to expand access to treatments for patients with serious mental illness, including treatment-resistant and complex conditions.
Under President Trump’s leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans.
Health and Human Services Secretary Robert F. Kennedy, Jr.
These medications have the potential to address the nation’s mental health crisis, including conditions like treatment-resistant depression, alcoholism and other serious mental health and substance abuse conditions.
FDA Commissioner Marty Makary, M.D., M.P.H.
As part of the initiative, the FDA is issuing national priority vouchers to three companies studying specific psychedelic compounds: psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder (PTSD).
The agency is also permitting an early-phase clinical study of noribogaine hydrochloride to proceed after receiving an Investigational New Drug (IND) submission.
The regulatory actions focus on serotonin-2A agonists and related products, a class of perception-altering psychedelic medications under investigation for their potential in treating serious mental health conditions.
FDA officials emphasized that while these therapies show promise, their development must be grounded in sound science and rigorous clinical evidence to ensure safety, and efficacy.
As this field moves forward, it is critical that their development is grounded in sound science and rigorous clinical evidence. We owe it to our nation’s veterans and all Americans who are suffering from these conditions to evaluate these potential therapies with urgency.
FDA Commissioner Marty Makary, M.D., M.P.H.
The announcements represent a coordinated federal effort to address gaps in mental health treatment, particularly for conditions that have not responded adequately to existing therapies.